Ovintiv Inc. (OVV)

Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.

Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.

Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.

Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.

Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.

Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.

Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.

FCF growth under 50% of VET's 770.60%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.

Negative 10Y revenue/share CAGR while VET stands at 104.74%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.

Negative 5Y CAGR while VET stands at 0.67%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.

Negative 3Y CAGR while VET stands at 9.90%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.

10Y OCF/share CAGR at 75-90% of VET's 83.27%. Bill Ackman would demand strategic changes to close the gap in long-term cash generation.

Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.

Negative 3Y OCF/share CAGR while VET stands at 2743.76%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.

Negative 10Y net income/share CAGR while VET is at 130.79%. Joel Greenblatt sees a major red flag in long-term profit erosion.

Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.

Negative 3Y CAGR while VET is 10.29%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.

Below 50% of VET's 158.60%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.

Negative 5Y equity/share growth while VET is at 59.86%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.

Negative 3Y equity/share growth while VET is at 35.76%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.

5Y dividend/share CAGR at 50-75% of VET's 11.68%. Martin Whitman might see a lagging policy in mid-term shareholder returns.

Both firms reduced dividends recently. Martin Whitman suspects broader macro or industry issues forcing cost and payout cuts.

Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.

Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.